20/20 Biolabs, Inc. (AIDX)
NASDAQ:AIDX
Want to see AIDX full AI Analyst Report?
Top Page
20/20 Biolabs, Inc.
(NASDAQ:AIDX)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.63
▼(-64.61% Downside)
Action:N/A
Date:06/23/26
The score is primarily constrained by weak financial performance—recent sustained losses, very large cash burn, and a 2025 shift to extremely high leverage with negative equity. Technicals also point to bearish momentum (below key moving averages and negative MACD), while valuation is limited by losses (negative P/E) and the absence of a dividend yield.
Positive Factors
Gross margin improvement
A near-30% gross margin indicates the core lab testing model can achieve healthier unit economics. Over 2–6 months this improvement supports a durable path toward breakeven if revenue stays stable or grows, since margins reflect underlying pricing and cost of goods sold in testing operations.
Negative Factors
Extremely high leverage
Very high debt and negative equity materially weaken financial flexibility and elevate refinancing risk. Over the coming months this constrains investment, increases fixed interest burdens, and could force asset sales or dilutive capital raises to avoid solvency stress.
Read all positive and negative factors
Positive Factors
Negative Factors
Gross margin improvement
A near-30% gross margin indicates the core lab testing model can achieve healthier unit economics. Over 2–6 months this improvement supports a durable path toward breakeven if revenue stays stable or grows, since margins reflect underlying pricing and cost of goods sold in testing operations.
Read all positive factors
20/20 Biolabs, Inc. (AIDX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.49M
Dividend YieldN/A
Average Volume (3M)N/A
Price to Earnings (P/E)―
Beta (1Y)2.70
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees13
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding10,611,528
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.82
Price to Book (P/B)-7.76
Price to Sales (P/S)72.96
P/FCF Ratio-0.08
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue0.11
Enterprise Value/Gross Profit0.60
Enterprise Value/Ebitda-0.03
Forecast
1Y Price Target
$5.00Price Target Upside180.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
20/20 Biolabs, Inc. Business Overview & Revenue Model
Company Description
20/20 GeneSystems, Inc. operates as a specialized clinical diagnostic company, focusing primarily on screening for cancer and analyzing viral infections. The firm offers advanced blood tests for the early detection of various cancers, including a ...
How the Company Makes Money
null...
20/20 Biolabs, Inc. Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
8
Very Negative
Cash Flow
10
Very Negative
| Breakdown | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.05M | 1.75M | 1.42M | 11.06M | 9.62M |
| Gross Profit | 604.54K | 360.31K | 109.14K | 5.12M | 4.69M |
| EBITDA | -3.33M | -5.53M | -6.19M | 1.97M | 2.07M |
| Net Income | -3.74M | -5.55M | -6.39M | 2.19M | 2.07M |
Balance Sheet | |||||
| Total Assets | 4.14B | 3.61M | 6.37M | 12.22M | 10.27M |
| Cash, Cash Equivalents and Short-Term Investments | 1.03B | 1.78M | 4.09M | 8.81M | 3.35M |
| Total Debt | 1.28B | 1.51M | 2.07M | 2.41M | 2.35M |
| Total Liabilities | 1.69B | 2.08M | 2.08M | 2.84M | 3.38M |
| Stockholders Equity | -19.23M | 1.53M | 4.29M | 9.37M | 6.89M |
Cash Flow | |||||
| Free Cash Flow | -1.92B | -2.60M | -4.64M | 5.54M | -1.30M |
| Operating Cash Flow | -1.92B | -2.60M | -4.63M | 5.80M | -1.07M |
| Investing Cash Flow | 0.00 | 0.00 | -43.76K | -462.55K | -228.15K |
| Financing Cash Flow | 1.16B | 293.33K | -45.99K | 112.60K | 1.19M |
20/20 Biolabs, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.